In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Marinus (NASDAQ: MRNS), with a price target of $13. The company’s shares closed yesterday at $7.85.
Yang said:
“We anticipate this will be an important catalyst for the shares and we outline our thoughts ahead of the data below. We see upside potential of 100%+ assuming convincing data including a clear dose response. We believe the downside is limited given the history of the compound and potential in other indications.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 24.5% and a 55.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $16.75 average price target.
See today’s analyst top recommended stocks >>
Based on Marinus’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6 million. In comparison, last year the company had a GAAP net loss of $4.55 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
